Editas Medicine, Inc.

NASDAQ:EDIT

Biotechnology

Healthcare
$1.77 +2.65%

+$0.07 today

Market cap
$273.18M
Beta
2.10
P/E (TTM)
-2.4
EPS (TTM)
-$1.11
52W Low $1.66High $4.54

Volume 1.99M

Average 2.06M

EDIT Pre-Tax Margin

Income before tax as a percentage of revenue.

Editas Medicine, Inc.NASDAQ: EDIT

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin widens to -882.4%

Pre-tax margin was -882.4% in Q1 FY2026, up 751.0 pp from a year earlier. On a trailing-twelve-month basis it was -281.6%, up 419.5 pp year over year. Over 3 fiscal years it widened by 723.2 pp.

Context

  • Pre-tax margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-882.4%-859.7 pp QoQ
Last fiscal yearDec 2025
-395.0%+338.7 pp YoY
LTMMar 2026
-281.6%+419.5 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+751.0 pp——
1 year+338.7 pp——
3 years+723.2 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-395.0%
Year-over-year change
+338.7pp

Pre-Tax Margin vs competitors

How EDIT compares with its peers on the latest reported figures

  • EDIT's LTM Mar 2026 pre-tax margin of -281.6% is the 3rd highest of the 7 companies compared; the peer median is -895.5%.
  • Its year-over-year change of +419.5 pp is the 3rd highest of 7, against a peer median of +317.7 pp.
  • Over three fiscal years its change of +723.2 pp compares with a peer median of +299.9 pp.
EDIT Competitors Peer median
Pre-Tax Margin for EDIT and competitors
Company Period LTM level YoY 3-year change
BEAMBeam Therapeutics Inc.LTM Jun 2026-54.7% +606.6 pp+411.7 pp
DTILPrecision BioSciences, Inc.LTM Mar 2026-98.7% -55.7 pp+154.5 pp
EDITEditas Medicine, Inc.LTM Mar 2026-281.6% +419.5 pp+723.2 pp
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-597.0% +557.1 pp+299.9 pp
CRBUCaribou Biosciences, Inc.LTM Mar 2026-1194.0% +296.9 pp-615.0 pp
CRSPCRISPR Therapeutics AGLTM Sep 2026-1802.2% -515.0 pp+132731.0 pp
PRMEPrime Medicine, Inc.LTM Mar 2026-4917.6% +338.4 pp—
BNTCBenitec Biopharma Inc.FY2025— ——
SCTXScribe Therapeutics Inc.—— ——
RCKTRocket Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding EDIT) -895.5%+317.7 pp+299.9 pp

Competitors are the stored peer set for EDIT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue25.54M19.71M78.12M32.31M40.52M
Cost of Revenue5.05M6.34M6.06M199.25M0
Gross Profit20.49M13.38M72.06M(166.93M)40.52M
Gross Margin80.2%67.9%92.2%-516.6%100.0%
Research & Development142.51M174.96M177.65M199.25M89.95M
Selling, General & Admin76.18M70.7M69.65M71.99M49.9M
Operating Expenses213.64M239.33M241.24M84.22M139.86M
Depreciation & Amortization5.05M6.34M6.06M5.81M5.28M
EBITDA(187.45M)(214.1M)(147.16M)(233.11M)(148.61M)
EBITDA Margin-733.8%-1086.1%-188.4%-721.4%-366.8%
Operating Income(193.15M)(225.95M)(169.18M)(251.15M)(99.34M)
Operating Margin-756.1%-1146.3%-216.6%-777.2%-245.2%
Interest Income607K5.52M17.57M14.06M8.31M
Interest Expense00006.17M
Other Income / Expenses644K5.52M15.96M14.06M(60.72M)
Income Before Tax(192.5M)(220.43M)(153.22M)(237.09M)(160.06M)
Pre-Tax Margin-753.6%-1118.3%-196.1%-733.7%-395.0%
Income Tax Expense00000
Net Income(192.5M)(220.43M)(153.22M)(237.09M)(160.06M)
Net Margin-753.6%-1118.3%-196.1%-733.7%-395.0%
EPS (Basic)(2.85)(3.21)(2.02)(2.88)(1.80)
EPS (Diluted)(2.85)(3.21)(2.02)(2.88)(1.80)
Weighted Avg Shares67.62M68.66M75.97M82.34M88.75M
Weighted Avg Shares (Diluted)67.62M68.66M75.97M82.34M88.75M

Editas Medicine, Inc.

NASDAQ:EDIT

Intrinsic Alpha fair value

Locked

Current Price

$1.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.